I'm LongbridgeAI, I can summarize articles.Enliven Therapeutics CMO Helen Louise Collins sold 5,000 common shares on June 17, 2026, for approximately USD 217,816. She exercised options for these shares at USD 2.48 each before selling them at a weighted average price between USD 42.83 and USD 44.74. Following the transaction, her direct shareholding decreased to 25,000, while her stock options increased to 121,268.
- Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised options for 5,000 shares at USD 2.48 on June 17, 2026. * Collins sold 5,000 shares the same day at weighted average prices of about USD 42.83 to USD 44.74. * Directly held common shares fell to 25,000 following the transactions. * Stock options held rose to 121,268, with an exercise price of USD 2.48. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000010), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here